<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01167751</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Heart-001</org_study_id>
    <nct_id>NCT01167751</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction</brief_title>
  <official_title>Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the important reasons for human dying is Ischemic heart disease (IHD). The most
      reason is coronary artery disease. Beside morbidity, IHD induce myocardial infarction and
      necrosis which due to congestive heart failure.

      One therapeutic method is cellular cardiomyoplasty, which is to produce and substitute the
      cardiac cells with stem cell transplantation. Cell therapy is a potential therapeutic method
      to prevent ventricular remodeling after acute myocardial infarction. Human and animal
      studies have shown that stem cell trans plantation to myocardial infarcted zone can improve
      heart contractile function.

      The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation
      in patients with myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Single Blind (Outcomes Assessor), Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Left ventricular ejection fraction at rest, measured by Dobutamine Stress Echocardiography</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional contractility in the AOI / Change in LV dimensions (left ventricular end systolic diameter [LVESD], left ventricular end diastolic diameter [LVEDD]) as assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in LVM index, LVEDV, LVESV</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>MNC implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BM derived MNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC 133 implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BM derived AC 133</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of cell carrier</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MNC</intervention_name>
    <description>Implantation of BM derived MNC</description>
    <arm_group_label>MNC implantation</arm_group_label>
    <other_name>MNC injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AC 133</intervention_name>
    <description>Implantation of BM derived AC133</description>
    <arm_group_label>AC 133 implantation</arm_group_label>
    <other_name>AC133 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Injection of cell carrier</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CABG candidate

          -  4 or more than 4 viable segment

          -  First anterior heart attack whit in 21 days to 3 month.

          -  St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by
             echocardiography.

          -  The target lesion had to be located in the left anterior descending (LAD) section.

          -  Myocardium thickness more than 3 mm.

          -  Negative pregnancy test (in women with child bearing potential)

        Exclusion Criteria:

          -  History of prior anterior myocardial infarction:

          -  Patient with regional wall motion abnormalities in the non-infarct region prior CABG

          -  Patient with anterior etiology of LV dysfunction (Known/ suspected non ischemic
             cardiomyopathy, previous anthracycline, known ethanol abuse (greater than 6 0z.
             Ethanol / day on a regular basis.

          -  Patient with significant valve disease defined as stenosis or regulation graded as
             greater than moderate (2+)

          -  Poor echocardiography window.

          -  Active infection or history of recurrent infection or positive test for syphilis
             (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l

          -  Documental terminal illness or malignancy.

          -  Previous bone marrow transplant

          -  Autoimmune disease (e. g Lupus, Multiple sclerosis)

          -  Any contraindication for bone - marrow aspiration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammadhassan Nasseri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghiatollah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD., PhD</last_name>
    <phone>+98-2122402486</phone>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>+98-2122402486</phone>
    <email>leila.arab@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Arab, MD</last_name>
      <phone>+98-21-22305236</phone>
      <email>leila.arab@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Roghayeh Fazeli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nasser Aghdami, MD., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leila Arab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehrnaz Namiri, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soura Mardpour, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
  </link>
  <reference>
    <citation>Ahmadi H, Baharvand H, Ashtiani SK, Soleimani M, Sadeghian H, Ardekani JM, Mehrjerdi NZ, Kouhkan A, Namiri M, Madani-Civi M, Fattahi F, Shahverdi A, Dizaji AV. Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction. Curr Neurovasc Res. 2007 Aug;4(3):153-60.</citation>
    <PMID>17691968</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 21, 2010</lastchanged_date>
  <firstreceived_date>July 19, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Hamid Gourabi, Chief</name_title>
    <organization>Royan Institute</organization>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Bone marrow stem cells</keyword>
  <keyword>AC133</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
</clinical_study>
